500 related articles for article (PubMed ID: 17412883)
21. The fatty-acid amide hydrolase inhibitor URB597 does not affect triacylglycerol hydrolysis in rat tissues.
Clapper JR; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
Pharmacol Res; 2006 Nov; 54(5):341-4. PubMed ID: 16935521
[TBL] [Abstract][Full Text] [Related]
22. Effects of URB597, an inhibitor of fatty acid amide hydrolase (FAAH), on analgesic activity of paracetamol.
Soukupová M; Palazzo E; De Chiaro M; Gatta L; Migliozzi AL; Guida F; Luongo L; Giordano C; Siniscalco D; De Novellis V; Marabese I; Krsiak M; Maione S
Neuro Endocrinol Lett; 2010; 31(4):507-11. PubMed ID: 20802454
[TBL] [Abstract][Full Text] [Related]
23. Activation of TRPA1 channels by the fatty acid amide hydrolase inhibitor 3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate (URB597).
Niforatos W; Zhang XF; Lake MR; Walter KA; Neelands T; Holzman TF; Scott VE; Faltynek CR; Moreland RB; Chen J
Mol Pharmacol; 2007 May; 71(5):1209-16. PubMed ID: 17314320
[TBL] [Abstract][Full Text] [Related]
24. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
25. Endocannabinoid modulation of scratching response in an acute allergenic model: a new prospective neural therapeutic target for pruritus.
Schlosburg JE; Boger DL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2009 Apr; 329(1):314-23. PubMed ID: 19168707
[TBL] [Abstract][Full Text] [Related]
26. Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.
Johnston TH; Huot P; Fox SH; Wakefield JD; Sykes KA; Bartolini WP; Milne GT; Pearson JP; Brotchie JM
J Pharmacol Exp Ther; 2011 Feb; 336(2):423-30. PubMed ID: 20966038
[TBL] [Abstract][Full Text] [Related]
27. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
28. Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase.
Naidu PS; Kinsey SG; Guo TL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2010 Jul; 334(1):182-90. PubMed ID: 20375198
[TBL] [Abstract][Full Text] [Related]
29. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain.
Jhaveri MD; Richardson D; Kendall DA; Barrett DA; Chapman V
J Neurosci; 2006 Dec; 26(51):13318-27. PubMed ID: 17182782
[TBL] [Abstract][Full Text] [Related]
30. Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
Slivicki RA; Saberi SA; Iyer V; Vemuri VK; Makriyannis A; Hohmann AG
J Pharmacol Exp Ther; 2018 Dec; 367(3):551-563. PubMed ID: 30275151
[TBL] [Abstract][Full Text] [Related]
31. Preservation of striatal cannabinoid CB1 receptor function correlates with the antianxiety effects of fatty acid amide hydrolase inhibition.
Rossi S; De Chiara V; Musella A; Sacchetti L; Cantarella C; Castelli M; Cavasinni F; Motta C; Studer V; Bernardi G; Cravatt BF; Maccarrone M; Usiello A; Centonze D
Mol Pharmacol; 2010 Aug; 78(2):260-8. PubMed ID: 20424126
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597).
Piomelli D; Tarzia G; Duranti A; Tontini A; Mor M; Compton TR; Dasse O; Monaghan EP; Parrott JA; Putman D
CNS Drug Rev; 2006; 12(1):21-38. PubMed ID: 16834756
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Fatty Acid Amide Hydrolase Improves Depressive-Like Behaviors Independent of Its Peripheral Antinociceptive Effects in a Rat Model of Neuropathic Pain.
Jiang HX; Ke BW; Liu J; Ma G; Hai KR; Gong DY; Yang Z; Zhou C
Anesth Analg; 2019 Aug; 129(2):587-597. PubMed ID: 29863609
[TBL] [Abstract][Full Text] [Related]
34. Activation of endocannabinoid transmission induces antidepressant-like effects in rats.
Adamczyk P; Gołda A; McCreary AC; Filip M; Przegaliński E
J Physiol Pharmacol; 2008 Jun; 59(2):217-28. PubMed ID: 18622041
[TBL] [Abstract][Full Text] [Related]
35. A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats.
Lee J; Di Marzo V; Brotchie JM
Neuropharmacology; 2006 Sep; 51(3):557-65. PubMed ID: 16806299
[TBL] [Abstract][Full Text] [Related]
36. Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system.
Okine BN; Norris LM; Woodhams S; Burston J; Patel A; Alexander SP; Barrett DA; Kendall DA; Bennett AJ; Chapman V
Br J Pharmacol; 2012 Oct; 167(3):627-40. PubMed ID: 22595021
[TBL] [Abstract][Full Text] [Related]
37. Protective role of cannabinoid CB1 receptors and vascular effects of chronic administration of FAAH inhibitor URB597 in DOCA-salt hypertensive rats.
Baranowska-Kuczko M; Kozłowska H; Kloza M; Karpińska O; Toczek M; Harasim E; Kasacka I; Malinowska B
Life Sci; 2016 Apr; 151():288-299. PubMed ID: 26969765
[TBL] [Abstract][Full Text] [Related]
38. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets.
Zhang D; Saraf A; Kolasa T; Bhatia P; Zheng GZ; Patel M; Lannoye GS; Richardson P; Stewart A; Rogers JC; Brioni JD; Surowy CS
Neuropharmacology; 2007 Mar; 52(4):1095-105. PubMed ID: 17217969
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of fatty acid amide hydrolase (FAAH) reduces spinal nociceptive responses and expression of spinal long-term potentiation (LTP).
Eriksen GS; Jacobsen LM; Mahmood A; Pedersen LM; Gjerstad J
Brain Res Bull; 2012 Feb; 87(2-3):234-7. PubMed ID: 22133920
[TBL] [Abstract][Full Text] [Related]
40. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD
J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
